ATAI Life Sciences NV, in collaboration with Beckley Psytech, has announced positive results from a Phase 2b study of BPL-003, a psychedelic therapy aimed at treating patients with treatment-resistant depression. The study achieved its primary and secondary endpoints, demonstrating rapid and durable antidepressive effects with a single 8 mg or 12 mg dose, and favorable tolerability with minimal in-clinic time. These results support the advancement of BPL-003 into Phase 3 clinical studies. ATAI and Beckley Psytech plan to engage with the U.S. Food and Drug Administration and other regulatory agencies to discuss the design of the Phase 3 trial. A conference call and live webcast to discuss the findings will be held on July 1, 2025, and an archived replay will be available on ATAI's corporate website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。